Last updated: May 24, 2026
Empagliflozin supply is concentrated around Boehringer Ingelheim (drug developer and brand owner for Jardiance) and a limited set of contract manufacturers for drug substance (API) and finished dosage forms (tablets). In practice, supplier discovery depends on the finished product manufacturer listed for each national product and the API manufacturer disclosed in dossiers (EMA/FDA), regulatory filings, and published excipient/CDMO disclosures.
Which companies supply empagliflozin API (drug substance) globally?
The empagliflozin API supply chain is tied to Boehringer Ingelheim’s commercial and manufacturing footprint and to Boehringer-approved external manufacturers disclosed in regulatory submissions. In most markets, finished product supply (tablets) flows through Boehringer’s network and select CDMOs that produce tablets under license or contract manufacturing.
Practical supplier sources used in diligence
- Regulatory listings for finished products (each strength and pack) that identify the manufacturer of the finished dosage form.
- Drug master files (DMFs) and API manufacturing disclosures used in CTD modules (module 3).
- Inspection and authority records that associate API and finished product sites with approvals.
- Public supply disruptions and shortage notices (national competent authorities often name responsible manufacturers).
API vs. finished product
- API (empagliflozin) suppliers are disclosed through dossier components and DMF references.
- Finished product suppliers are typically more visible through national product authorizations and labeling.
Who supplies Jardiance (empagliflozin) tablets by market and strength?
Jardiance tablet supply varies by country, strength (10 mg and 25 mg), and pack presentation. For supplier mapping, the authoritative method is to pull the manufacturer of the medicinal product from local marketing authorizations and labeling.
Supplier discovery workflow used by pharma procurement
- Identify the Marketing Authorization Holder (MAH) and the site(s) listed as manufacturer/release for the finished tablets.
- Cross-check the site’s role (batch release vs. packaging vs. manufacturing).
- Align the table strength with the specific label (10 mg and 25 mg can have different release sites depending on market and time).
What contract manufacturers make empagliflozin tablets under Boehringer licenses?
Contract manufacturing for empagliflozin tablets is typically performed by CDMOs with capability for solid oral dosage forms (tablet compression, coating, blistering and packaging). The most reliable source is the finished product “manufacturer” named on the label in each country, because it captures both internal and external manufacturing.
What to look for in supplier documents
- Manufacturing site address consistency across strengths
- GMP certificate scope for solid dose forms and tablet release
- Whether the label distinguishes:
- manufacturing
- batch control/release
- packaging
- secondary packaging and labeling
How do you identify the empagliflozin API supplier from regulatory filings (EMA/FDA)?
For API supplier diligence, CTD module 3 is the key. Dossiers generally disclose:
- the API manufacturer(s)
- the manufacturing process category (manufacturing steps and site)
- whether the API comes from a single source or multi-source network
EMA-based approach
- Use the European public assessment framework (EPAR) and national-level documentation where available.
- Track the “manufacturer” or “manufacturer of the active substance” in the product information.
FDA-based approach
- Identify the API reference in:
- the listed drug’s regulatory history and application references
- DMF cross-references in ANDA/505(b)(2) submissions (when publicly available through later generics/BR studies)
- For finished products, use labeling for the finished manufacturing and batch-release site.
What excipient and packaging suppliers matter for empagliflozin tablets supply risk?
While the user asked for “suppliers,” procurement risk for empagliflozin tablets is often driven by the surrounding supply chain:
- film coating system availability for the tablet
- blister systems and packaging inks
- desiccant and carton printing capacity for secondary packaging
In force majeure periods, batch release can fail even when API supply is intact. Supplier mapping should therefore include:
- packaging material suppliers listed through packaging qualification documentation
- blister and carton components used for the national presentation
Where does empagliflozin originate in the supply chain: single-source or multi-source?
Commercial Sourcing Models commonly evolve:
- Early launch and initial commercial ramp often use limited validated sites.
- Later stages add additional validated API or finished product sites to expand capacity and reduce lead time risk.
For empagliflozin, multi-site manufacturing is common at the finished dosage level given the global distribution footprint of Jardiance.
Which generic or biosimilar suppliers might reveal empagliflozin API sources?
Empagliflozin is a small molecule. It does not have biosimilar pathways. However, generic tablet entrants and 505(b)(2) products often reveal:
- API manufacturer and site references (through DMF cross-references when publicly traceable)
- finished product manufacturing sites (through labeling and approval documents)
This information is most actionable when mapped strength-by-strength (10 mg/25 mg) and when aligned to specific approvals and launch geographies.
What patent and regulatory status affects empagliflozin supplier availability?
Supplier availability is not driven only by manufacturing capacity. IP and regulatory status can affect:
- the ease of access to validated API routes
- the ability of generics to secure supply of comparable grades
- whether entrants rely on alternative API sources
For procurement planning, supplier feasibility should be reviewed alongside:
- regulatory approval status of the finished product sites
- validated methods and equivalence requirements
- cross-border shipping constraints and batch release timing
Key tables: supplier mapping framework for empagliflozin procurement
Table 1. Empagliflozin supply mapping fields
| Supplier type |
What you should capture |
Where it appears in records |
| API manufacturer(s) |
empagliflozin site address, GMP scope, DMF/ASMF reference |
CTD module 3, DMF/ASMF-linked disclosures |
| Finished dosage manufacturer |
tablet manufacturing and batch release site |
product labeling, marketing authorization dossiers |
| Packaging manufacturer |
blistering, secondary packaging, labeling contractor |
manufacturing authorization and batch records |
| Quality release |
QP/batch release role and regulatory status |
label/manufacturing section, authority documents |
Table 2. Strength-specific supplier mapping
| Country |
Product |
Strength |
Finished product manufacturer(s) |
API manufacturer(s) |
| To fill from local label |
Jardiance |
10 mg |
site listed on label |
“manufacturer of active substance” in dossier |
| To fill from local label |
Jardiance |
25 mg |
site listed on label |
“manufacturer of active substance” in dossier |
What is the most defensible shortlist of empagliflozin suppliers for due diligence?
A defensible shortlist is built from the manufacturers named on the approved finished product labels in key target markets, then backfilled to the API source using module 3 dossier disclosures for those same product lines. This yields:
- fewer suppliers than attempting to infer API producers from online vendor catalogs
- higher confidence because the suppliers have been accepted by regulators for the specific marketed dosage forms
Key Takeaways
- Empagliflozin supply is anchored by Boehringer Ingelheim’s global manufacturing and release network for Jardiance.
- API supplier identification is most reliable through regulatory dossier disclosures (CTD module 3) and DMF/ASMF-linked references.
- Finished dosage supplier identification is most reliable through national product labeling and marketing authorization documentation, strength-by-strength.
- Packaging and blistering supply can still create bottlenecks even when API availability is adequate.
FAQs
-
How do I find the manufacturer of the active substance for empagliflozin in the EU?
Use the marketing authorization product information and dossier sections identifying “manufacturer of the active substance,” typically tied to module 3 CTD content.
-
Which document identifies the batch release site for Jardiance tablets?
The manufacturer and batch release information is shown in the finished product labeling and the relevant sections of the marketing authorization dossier.
-
Can empagliflozin be supplied through multiple API DMFs for the same marketed product?
Yes, multi-source API arrangements are common, and the supplier list for the active substance can include multiple validated manufacturing sites referenced in dossiers.
-
How do I map empagliflozin tablet suppliers across countries efficiently?
Build a market-by-market table using the label’s “manufacturer” field for each strength and packaging presentation, then reconcile to the active substance manufacturer(s) from the associated dossier.
-
What supply risks most frequently affect empagliflozin tablet availability?
Bottlenecks often shift to tablet coating, blistering, and packaging execution, plus batch release timing, not only API availability.
References
- European Medicines Agency (EMA). Jardiance (empagliflozin) EPAR and related product information.
- U.S. FDA. Jardiance (empagliflozin) prescribing information and FDA label/manufacturing information for marketed products.
- FDA. ANDA and 505(b)(2) publicly available application components and labeling references (for generic/bridge products disclosing API and manufacturing sites).
